18-Month Below-the-Knee data with MedAlliance's SELUTION SLRtrade; presented as Late Breaking Trial at VIVA

18-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21.

Related Keywords

Singapore ,Geneva ,Genè ,Switzerland ,Tang Tjun Yip ,Cell Adherent Technology ,Hospital Department Of Vascular Surgery ,Late Breaking Clinical Trial ,Critical Limb Ischemia ,Target Lesion Revascularization ,Amputation Free Survival ,Singapore General Hospital ,Associate Professors Chong Tze Tec ,Headsenior Consultant ,Senior Consultant ,Peripheral Artery Disease ,Medalliance Chairman ,Switzerland News ,Bserved ,Coronary ,Study ,Artery ,Artery Disease ,Dealing ,Ontrolled ,Been With ,